Patents Assigned to DCIC Biopharmaceutical Limited
  • MEDICATION AGAINST ESTROGEN-RECEPTOR b (ER.beta) POSITIVE BREAST TUMOR
    Publication number: 20220054501
    Abstract: The present invention relates to the field of medicine, and refers to the steroid compound 4-hydroxyandrost-4-ene-3,17-dione (4-OHA) or ester thereof, as a prodrug for use in the treatment of a patient suffering from estrogen-receptor ? (ER?) positive breast tumour. The present invention further relates to a pharmaceutical composition comprising said steroid compound for topical application, and the use of said steroid compound in a pre-surgical topical treatment of ER?-positive breast cancer tissue.
    Type: Application
    Filed: December 13, 2019
    Publication date: February 24, 2022
    Applicant: DCIC Biopharmaceutical Limited
    Inventor: Heinrich Wieland